IJERPH, Vol. 17, Pages 1110: Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review

IJERPH, Vol. 17, Pages 1110: Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review International Journal of Environmental Research and Public Health doi: 10.3390/ijerph17031110 Authors: Töreyin Ghosh Göksel Göksel Godderis Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers of cancer and asbestos-related diseases show encouraging results. The aim of this systematic review was to provide an overview on the current knowledge about exhaled breath analysis in MPM diagnosis. A systematic review was conducted on MEDLINE (PubMed), EMBASE and Web of Science databases to identify relevant studies. Quality assessment was done by the Newcastle–Ottawa Scale. Six studies were identified, all of which showed fair quality and explored volatile organic compounds (VOC) based breath profile using Gas Chromatography Coupled to Mass Spectrometry (GC–MS), Ion Mobility Spectrometry Coupled to Multi-capillary Columns (IMS–MCC) or pattern-recognition technologies. Sample sizes varied between 39 and 330. Some compounds (i.e, cyclohexane, P3, P5, P50, P71, diethyl ether, limonene, nonanal, VOC IK 1287) that can be indicative of MPM development in asbestos exposed population were identified with high diagnostic accuracy rates. E-nose...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Review Source Type: research

Related Links:

Conditions:   Thoracic Cancer;   Non-small Cell Lung Cancer;   Small-cell Lung Cancer;   Pleural Mesothelioma Intervention:   Other: eRAPID online symptom monitoring in lung cancer Sponsors:   University of Leeds;   The Leeds Teaching Hospitals NHS Trust;   Iqvia Pty Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
As the U.S. comes to grips with the challenges of the COVID-19 pandemic, mesothelioma cancer survivors face additional hurdles, including difficulty receiving care. Patients currently undergoing treatment for cancer and those who are immunocompromised are at greater risk of serious health issues if they contract COVID-19, according to the Centers for Disease Control and Prevention. “Cancer patients are a high-risk group and should be extra vigilant in terms of isolation precautions. They should follow the medical authorities’ instructions,” Dr. Ory Wiesel, a thoracic surgeon at Maimonides Medical Center ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant mesothelioma (MM), especially its more frequent form, malignant pleural mesothelioma (MPM), is a devastating thoracic cancer with limited therapeutic options. Recently, clinical trials that used immunotherapy strategies have yielded promising results, but the benefits are restricted to a limited number of patients. To develop new therapeutic strategies and define predictors of treatment response to existing therapy, better knowledge of the cellular and molecular mechanisms of MM tumors and sound preclinical models are needed. This review aims to provide an overview of our present knowledge and issues on both subj...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Raw asbestos imported to the United States dropped significantly in 2019, according to the recently released U.S. Geological Survey Mineral Commodity Summaries report. The U.S. imported an estimated 100 metric tons of asbestos last year. It’s the smallest amount since records were first kept in 1910, long before the mineral became a major part of the construction industry in America. That number is in sharp contrast to the 681 metric tons imported in 2018. All imported asbestos went to the chloralkali industry — for the second consecutive year — to use in the manufacturing of semipermeable diaphragms for ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Lung Cancer;   Head and Neck Cancer;   Bladder Cancer;   Esophageal Cancer;   Mesothelioma Interventions:   Biological: S-488210;   Biological: S-488211 Sponsor:   Shionogi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The plant-based substance curcumin could soon be included in the multidisciplinary treatment of malignant mesothelioma, according to a recent multicenter, international study review. Curcumin, an active compound found in the common culinary spice turmeric, has been used for decades by some as an anti-inflammatory, complementary medicine for many ailments. It may soon take a more prominent role with mesothelioma, an aggressive cancer with no definitive cure. “Our hope is that, in the not-too-distant future, it could be part of new therapeutic strategies for mesothelioma,” Dr. Antonio Giordano, director of Sbarro...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsThis study indicated that CT ‐707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose‐expansion phase recruitment has started.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Scientist Ian Blair at the University of Pennsylvania School of Medicine believes his team is close to identifying the variant of a blood-based biomarker that could diagnose asbestos disease in its earliest stages. If successful, it could clear the path to a more treatable — and potentially curable — stage of malignant mesothelioma cancer. “This could be a big deal. We’re trying to become the first,” Blair told The Mesothelioma Center at Asbestos.com. “We hope to have it within the year.” The potential breakthrough involves the HMGB1 (High-Mobility Group Box 1) chromosomal protein...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
PMID: 32169964 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
A new clinical trial is testing an innovative approach to immunotherapy that could change the way antibodies target pleural mesothelioma tumors. Researchers at eight cancer centers across the U.S. are examining the safety and efficacy of INBRX-109, a unique antibody structure developed to bind with and destroy mesothelioma tumor cells without harming healthy tissue. Enrollment for mesothelioma patients is ongoing for the second stage of the first-in-humans trial. Safety and efficacy reports are expected in the second quarter of 2020. The first stage of the trial reached its endpoint with no reports of toxicity or intoleran...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Databases & Libraries | Environmental Health | International Medicine & Public Health | Mesothelioma | Nutrition | Organic | Science | Study